These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11077843)

  • 1. [Antibacterial therapy in pulmonology].
    Nonikov VB
    Probl Tuberk; 2000; (5):8-11. PubMed ID: 11077843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
    Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
    J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibiotic therapy of bronchial infections. 2: Community acquired and nosocomial pneumonias].
    Buchenroth M
    MMW Fortschr Med; 1999 Dec; 141(49-50):48-50. PubMed ID: 10726149
    [No Abstract]   [Full Text] [Related]  

  • 4. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
    Roig J; Casal J; Gispert P; Gea E
    Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
    Bartlett JG
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T; Petermann W; Schürmann D; Bauer TT; Reimnitz P;
    Clin Infect Dis; 2005 Dec; 41(12):1697-705. PubMed ID: 16288390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital-acquired respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
    Akova M
    Int J Clin Pract Suppl; 2002 Mar; (125):19-27; discussion 37-9. PubMed ID: 12014853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trends in the treatment of pneumonia].
    Grassi V; Romanelli G
    Recenti Prog Med; 1999; 90(7-8):373-9. PubMed ID: 10429515
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotics in childhood pneumonia.
    Hale KA; Isaacs D
    Paediatr Respir Rev; 2006 Jun; 7(2):145-51. PubMed ID: 16765302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
    Rahav G; Fidel J; Gibor Y; Shapiro M
    Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 20. [Uncomplicated community-acquired pneumonia. Under control in 3 treatment days].
    MMW Fortschr Med; 2003 Jan; 145(3-4):58. PubMed ID: 12619240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.